Navigation Links
Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
Date:6/20/2011

SAN DIEGO, June 20, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentations include a late-breaking abstract on the safety and efficacy of Aspart-PH20, a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog®, administered via continuous pump infusion in type 1 diabetes patients over three days. A second presentation tests the safety and evaluates whether regular insulin can be made as fast as an analog. The presentations are scheduled as follows:

Oral Presentation
Saturday – June 25, 2011
1:45 – 2:00 p.m.: Comparison of Human Hyaluronidase + Recombinant Human Insulin (RHI) vs. Insulin Lispro in a Basal-Bolus Regimen in Patients with Type 1 Diabetes (T1DM)
Abstract Number: 0069-OR
Presented during session: Pharmacologic Treatment of Diabetes-Insulin Therapy

Late Breaker Poster – Insulin Pump Study
Sunday – June 26, 2011
12:00 – 2:00 p.m.: Addition of Human Hyaluronidase to Rapid Analog Insulin Reduces the Absolute Variability of Early Insulin Absorption across Infusion Set Life
Abstract Number: 0027-LB
Location: Hall B – Poster Hall

Poster
Sunday – June 26, 2011
1:00 – 2:00 p.m.: Human Hyaluronidase Coinjection Consistently Accelerates Prandial Insulin Pharmacokinetics (PK) and Glucodynamics (GD) across Studies and Populations
Abstract Number: 0965-P
Location: Hall B – Poster Hall

Abstracts for these presentations may be found by visiting the ADA Scientific Sessions Web site.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Baxter, Roche, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including immunoglobulin, Herceptin®, MabThera®, Cinryze® and alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Halozyme Contact
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264
ruhl@halozyme.com

Media Contact
Ligia Santos
415-946-1083
lsantos@invigoratepr.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO ... ASTER Labs ), Inc. has been selected for membership in ARCS Alumni ...
(Date:10/11/2017)... ... ... is a basic first aid supply for any work environment, but most personal eye wash ... if a dangerous substance enters both eyes? It’s one less decision, and likely quicker response ... piece. , “Whether its dirt and debris, or an acid or alkali, getting anything in ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
Breaking Biology Technology:
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):